We are happy to announce that on the 22nd of November 2022 One-carbon Therapeutics received confirmation from the US patent office that a key patent covering the company’s leading drug candidate for the treatment of cancers, inflammation, autoimmune diseases has been granted. The granting of this patent establishes our strong IP portfolio and lays the foundation for further clinical development for different indications with great unmet medical needs.
Detailed mode of action of the MTHFD1/2 inhibitor TH9619 now published in Nature Metabolism
The One-carbon Therapeutics team is proud and excited to share
